Login
$TNYA
$0.34 +$0.01 (1.92%) After hours

$TNYA SEC Filings

Filed On Filing
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

23 Oct 2026 DEFA14A
23 Oct 2026 DEF 14A
13 Oct 2026 PRE 14A
11 Sep 2026 Form 4: Ali Faraz, Director

Received 122,000 shares as a grant or award · Granted 732,500 Stock Option (Right to buy)

11 Sep 2026 Form 4: Tingley Whittemore, Chief Medical Officer

Received 49,000 shares as a grant or award · Granted 293,000 Stock Option (Right to buy)

24 Aug 2026 SCHEDULE 13G
17 Aug 2026 Form 4: Ali Faraz, Director

Sold 22,232 shares ($15.8K)

17 Aug 2026 Form 4: Tingley Whittemore, Chief Medical Officer

Sold 7,424 shares ($5.27K)

17 Aug 2026 144
17 Aug 2026 144
05 Aug 2026 S-8
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics

14 Jul 2026 Form 3: Hyllengren Eric J, Chief Financial Officer

No securities owned

14 Jul 2026 Form 4: Hyllengren Eric J, Chief Financial Officer

Granted 1,650,000 Stock Option (Right to buy)

02 Jul 2026 8-K: Termination of a Material Definitive Agreement

On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenu...

29 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

On behalf of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), I am pleased to invite you to join the Company as Chief Financial Officer, reporting to the Company’s Chief Executive Officer. Your primary work location will be Thousan...

29 May 2026 Form 4: Williams R Sanders, Director

Granted 120,000 Stock Option (Right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support